Budesonide
Unchecked
Budesonide
Pulmicort (inhaled), Rhinocort (intranasal), Entocort EC and Uceris (enteric-coated oral for IBD), Symbicort (with formoterol)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Asthma controller0, COPD0, Allergic rhinitis (intranasal)0, Croup (nebulized)0, Crohn's disease (oral enteric-coated, ileal/right-colonic disease)0, Ulcerative colitis (Uceris)0
Pharmacy
Starting dose
ICS Pulmicort Flexhaler 180-360 mcg BID; intranasal Rhinocort 64 mcg/spray, 1-2 sprays/nostril daily; Entocort EC 9 mg PO daily for active Crohn's; Symbicort 80/4.5 or 160/4.5 mcg, 2 puffs BID
Preparations
Pulmicort Flexhaler DPI 90, 180 mcg/dose; Pulmicort Respules 0.25, 0.5, 1 mg/2 mL nebulized; Rhinocort intranasal 32 mcg/spray; Entocort EC 3 mg capsules; Uceris 9 mg ER tablets and rectal foam
US FDA Max
ICS ~1280 mcg/d; intranasal 256 mcg/d; Entocort 9 mg/d standard
Pharmacology
Routes
Inhaled, intranasal, oral (enteric-coated, rectal foam), nebulized
Onset
Inhaled: bronchial effect 1-2 weeks; oral GI effect 1-2 weeks
Duration
12-24 hours
Half-life
~2-3.6 hours (plasma)[1]
Bioavailability
~6-13% inhaled lung deposition; ~10% oral (Entocort EC; extensive first-pass via CYP3A4 — this is the basis of the favorable hepatic-targeted local-effect profile in IBD)[1]
Pregnancy
Long the preferred ICS in pregnancy (Pulmicort) due to the most pregnancy data among the class.[citation needed]
Legal status
OTC (intranasal Rhinocort Allergy) and Rx-only (other forms) in US
Purported mechanism
Budesonide is a high-potency glucocorticoid receptor agonist designed with high topical receptor affinity and extensive hepatic first-pass to minimize systemic glucocorticoid exposure.0 The first-pass property is the basis of enteric-coated oral formulations for IBD: drug is delivered locally to ileum/right colon (Entocort EC) or to colon (Uceris), then largely inactivated on first hepatic pass, sparing systemic steroid exposure. CYP3A4 substrate; strong CYP3A4 inhibitors (ritonavir, ketoconazole) can raise systemic levels enough to produce iatrogenic Cushing's[1].
References
[edit | edit source]- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Pulmicort Flexhaler (budesonide), AstraZeneca, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021949s041lbl.pdf